Centene Corporation (CNC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed sentiment. Positive aspects include increased EPS forecast, margin improvements, and operational focus. However, concerns arise from potential investment losses, higher tax rates, and lack of breakeven in Medicare Advantage by 2026. The Q&A section highlights cautious optimism with some uncertainties, such as Medicaid trends and management's vague responses. Overall, the sentiment is balanced, resulting in a neutral outlook.
Key Financial Performance
Fourth Quarter Adjusted Diluted Loss Per Share $1.19, contributing to a full year 2025 adjusted diluted EPS of $2.08. The year was challenging, but disciplined execution enabled the company to close slightly ahead of expectations.
Medicaid Health Benefits Ratio (HBR) 93.0% in Q4, representing a 40 basis points sequential improvement and 190 basis points improvement from Q2 levels. Improvement attributed to strong cross-enterprise execution and cost management.
Composite Rate Adjustment for Medicaid Approximately 5.5% above 2024 levels. This was consistent with prior commentary and reflects adjustments based on acuity and trend dynamics over the last two years.
Commercial Segment HBR 1% higher than forecasted in Q4 due to a 2023 CMS reconciliation and costs related to No Surprises Act disputes. However, current period medical costs and trends were slightly better than expectations.
Medicare Segment HBR Improved in Q4, with strong results in Medicare Advantage and PDP businesses. Adjustments to provider receivables slightly elevated HBR compared to expectations.
Premium and Service Revenue $174.6 billion for full year 2025. This reflects the overall scale of the business and its operations.
Debt Reduction $189 million in Q4, ending with a debt-to-capital ratio of 46.5%. This reflects ongoing efforts to deleverage the balance sheet.
Medical Claims Liability $20.5 billion, representing 46 days in claims payable. This was a decrease of 2 days compared to Q3 2025, driven by payouts of state-directed payments and elimination of the Medicare premium deficiency reserve.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Medicaid profitability: Improved profitability with a health benefits ratio of 93.0% in Q4, showing sequential improvement and better trajectory for 2026.
Marketplace performance: Medical cost trends slightly better than expected in Q4, with actions taken to address No Surprises Act disputes and fraudulent claims.
Medicare Advantage: Strong results in 2025, with a focus on breakeven by 2027 and improved product positioning for 2026.
Medicaid membership: Membership slightly declined to 12.5 million by the end of 2025, with further attrition expected in 2026.
Marketplace enrollment: Membership expected to stabilize at 3.5 million by Q1 2026, with a shift towards Bronze plans.
Medicare PDP growth: Part D enrollment tracking high single-digit growth for 2026, with a focus on dual-eligible members.
Fraud detection and cost management: Implemented data-driven programs to reduce fraud and unnecessary utilization in Medicaid, including an ABA task force.
AI and technology integration: Enhanced operations with AI for prior authorization, call center operations, and fraud detection.
Medicare Advantage strategy: Refined footprint and value proposition for Medicaid beneficiaries, aiming for breakeven by 2027.
Policy advocacy: Advocating for reforms in the No Surprises Act and individual marketplace to stabilize costs and improve affordability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicaid profitability: Behavioral health, home health, and high-cost drugs are driving excess trends, creating financial pressure. Fraud within the provider ecosystem and unnecessary utilization are also challenges.
Marketplace business: The No Surprises Act (NSA) has been exploited by market participants, leading to increased costs. Aggressive legal actions are being taken to address fraudulent claims. Expiration of enhanced advanced premium tax credits (eAPTC) has created uncertainty and impacted membership.
Medicare Advantage: The business is not yet profitable, with a goal of breakeven by 2027. Provider contract adjustments and rate pressures from the 2027 advanced notice are challenges.
General operational risks: Policy-related variability and landscape volatility continue to influence core business lines. Fraud detection and reduction remain critical to protect program integrity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Adjusted EPS: Expected to be greater than $3, representing over 40% year-over-year growth.
Medicaid Business: Focus on restoring profitability through network optimization, clinical program enhancements, rate advocacy, and fraud reduction. Stable Medicaid HBR expected in 2026.
Marketplace Business: Anticipates meaningful margin recovery in 2026. Membership expected to end Q1 at approximately 3.5 million, with slight attrition thereafter. Bronze plan enrollment to increase to over 30% of total membership.
Medicare Advantage: Targeting breakeven results by 2027. Membership expected to decline in 2026 as part of a strategic refinement.
Medicare PDP: Enrollment projected to grow by high single-digit percentage in 2026. Initial pretax margin forecasted around 2%.
Revenue Projections: 2026 premium and service revenue expected to range between $170 billion and $174 billion.
Consolidated HBR: Expected to range between 90.9% and 91.7% in 2026, with a 60 basis point improvement from 2025.
SG&A Expense Ratio: Expected to remain stable in 2026.
Capital Deployment: No share buybacks included in 2026 guidance; focus on debt reduction and other capital deployment opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the 4.5% Medicaid rate expectation for 2026 and whether it is conservative?
A:The 4.5% rate expectation for 2026 is considered prudent. The company has the benefit of two years of data on acuity dynamics and trend step-ups, which inform rate decisions. The 2025 rates matured favorably, ending at a composite rate of 5.5%. The company has also worked to bend trends, contributing to the flat HBR year-over-year assumption.
Q:What was the Medicaid trend in 2025, and how does it compare to the 4.5% assumption for 2026?
A:The 2025 trend was in the mid-6% range, while the 2026 assumption is in the mid-4% range. The 2026 assumption reflects a net trend, considering elevated baselines and actions taken in 2025 to bend trends. The company also noted program changes like high-cost drug carve-outs and PBM control shifts as factors influencing the trend.
Q:Can you discuss the confidence and visibility in the exchanges, particularly regarding the metal tier shift and margin improvement?
A:The company has confidence in margin improvement for 2026 due to repricing and repositioning efforts in 2025, which included a mid-30% pricing increase. Membership distribution has shifted, with Bronze plans increasing to over 30%. Historical data on Bronze plans pre-eAPTCs was used to re-underwrite assumptions. The company also reduced its footprint in low-cost Bronze areas to manage risks.
Q:What are the expectations for Medicaid membership attrition and its impact on acuity assumptions?
A:The company expects continued membership attrition in 2026, consistent with 2025 trends, including program changes like the Florida CMS program rolling off and a subset of the New York essential plan. These factors are considered in guidance, with a 5%-6% reduction in member months expected for the year.
Q:How does the actuarial soundness look-back process work, and how is the company addressing rate adjustments during periods of disruption?
A:The company is focused on shortening the look-back period and including recent data in the actuarial process. Lessons from 2025, such as in-year rate corrections like Florida CMS, are being applied. The company is also engaging with states to discuss program refinements as an alternative to rate adjustments.
Q:What are the segment margin expectations for 2026, and how does the lack of a PDR in Medicare Advantage impact breakeven targets?
A:Medicaid margins are expected to remain stable, while the commercial segment (marketplace) is projected to achieve a 4% pretax margin. Medicare Advantage is not expected to breakeven in 2026 but will operate at a slight loss. The lack of a PDR indicates progress toward breakeven, with further improvement expected by 2027.
Q:How does the company explain its different Medicaid outlook compared to peers, and what role does the PBM contract play?
A:The company attributes its outlook to an elevated baseline in 2025, favorable rate maturation, and aggressive execution in the back half of 2025. The PBM contract is tailored, transparent, and flexible, allowing the company to benefit from its $60 billion pharmacy spend and collaborate effectively with its PBM partner.
Q:What are the dynamics of the Part D business, particularly regarding LIS and non-LIS populations post-IRA?
A:The company grew its Part D membership from 8.1 million to 8.7 million, with a mix of LIS and non-LIS populations. The IRA's impact on non-LIS populations was considered in 2026 bids, and the company expects to maintain profitability in both segments. The expanded risk corridor in 2025 provided stability, and the company is well-positioned for 2026.
Q:What are the Medicaid trends for 2025 and 2026, and how are states' benefit design changes impacting the business?
A:Core Medicaid trends in 2025 were driven by behavioral health, home health, and high-cost drugs, with behavioral health accounting for 50% of excess trend. The company has taken actions to mitigate these trends, contributing to a 93.0% HBR at year-end. States' benefit design changes are being monitored, and competitive dynamics are being influenced by rate pressures on smaller plans.
Q:What is the company's view on exchange Bronze plan utilization patterns and their impact on margins?
A:The company has not observed any alarming utilization patterns in Bronze plans so far in 2026. Trade-down dynamics were anticipated and factored into pricing. Historical data on Bronze plans pre-eAPTCs was used to inform assumptions, and the company is monitoring utilization closely.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific reasons for differences in Medicaid outlook compared to peers, instead focusing on general factors like elevated baselines and execution. Additionally, while discussing actuarial soundness and rate adjustments, management used vague language about 'lessons learned' and 'proof points,' without providing concrete examples or timelines for improvement.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABA
Advantage line
Ambetter
Bronze
Marketplace
Medicaid profitability
Medicaid year
NSA
President Investor
Senior Vice
Wakely
analytics
approach
beneficiary
capability
center
demographic
dispute
driver
end press
engagement
enterprise
experience member
flu
foundation
hour
intervention
line expectation
market participant
mission
partner program
payment
plan year
point improvement
power
program design
program reform
provider
quality care
release presentation
review
therapy
trend marketplace
year member
CNC Transcript
Centene Corporation (CNC) Q4 2025 Earnings Call Transcript
Unknown2-6
The earnings call reveals a mixed sentiment. Positive aspects include increased EPS forecast, margin improvements, and operational focus. However, concerns arise from potential investment losses, higher tax rates, and lack of breakeven in Medicare Advantage by 2026. The Q&A section highlights cautious optimism with some uncertainties, such as Medicaid trends and management's vague responses. Overall, the sentiment is balanced, resulting in a neutral outlook.
Centene Corporation (CNC) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Centene Corporation (CNC) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call summary indicates challenges with adjusted EPS guidance reduction, Medicaid attrition, and Marketplace business running below breakeven. The Q&A section highlights concerns over market stability, competitive positioning, and lack of clear guidance on Medicaid margins and exchange stability. Despite some positive aspects like improved SG&A ratio and cash flow, the overall sentiment is negative due to significant financial and operational uncertainties, particularly in the Marketplace and Medicaid segments. This is likely to lead to a negative stock price movement in the short term.
Centene Corporation (CNC) Q2 2025 Earnings Call Transcript
Positive7-25
The earnings call summary indicates strong financial performance with revenue growth, strategic Medicaid and Medicare wins, and operational efficiency improvements. The Q&A session highlighted management's confidence in future earnings and margin improvements, despite some market challenges. The positive sentiment is further supported by the increased revenue guidance and optimistic outlook for 2026. Although there are uncertainties regarding market contractions and Medicaid adjustments, the overall outlook is positive, with expected higher earnings and strategic measures in place to address potential risks.
CNC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
